Citations

Clear

2285 citation(s) found for "Yu, Anthony".

Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine
Compton, Carolyn C. , Robb, James A., Anderson, Matthew W. , Berry, Anna B. , Birdsong, George , Bloom, Kenneth J., Branton, Philip A. , Crothers, Jessica W. , Cushman‐Vokoun, Allison M. , Hicks, David G., Khoury, Joseph D. , Laser, Jordan , Marshall, Carrie B. , Misialek, Michael J., Natale, Kristen E. , Nowak, Jan A. , Olson, Damon R. , Pfeifer, John D. , Schade, Andrew E., Vance, Gail H. , Walk, Eric , Yohe, Sophia , Birdsong, George G, Nowak, Jan Anthony, Olson, Damon, Schade, Andrew, Walk, Eric E, Yohe, Sophia Louise, Berry, Anna , Olson, Damon R

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 22, 2019 | Volume: 143 | Issue: 11 | Pages: 1346-1363

10.5858/arpa.2019-0009-sa | PMID 31329478 Get It

Biospecimens acquired during routine medical practice are the primary sources of molecular information about patients and their diseases that underlies precision medicine and translational research. In cancer care, molecular analysis of biospecimens is especially common because it often determines treatment choices and may be used to monitor therapy in real time. However, patient specimens are collected, handled, and processed according to routine clinical procedures during which they are subjected to factors that may alter their molecular quality and composition. Such artefactual alteration may skew data from molecular analyses, render analysis data uninterpretable, or even preclude analysis altogether if the integrity of a specimen is severely compromised. As a result, patient care and safety may be affected, and medical research dependent on patient samples may be compromised. Despite these issues, there is currently no requirement to control or record preanalytical variables in clinical practice with the single exception of breast cancer tissue handled according to the guideline jointly developed by the American Society of Clinical Oncology and College of American Pathologists (CAP) and enforced through the CAP Laboratory Accreditation Program. Recognizing the importance of molecular data derived from patient specimens, the CAP Personalized Healthcare Committee established the Preanalytics for Precision Medicine Project Team to develop a basic set of evidence-based recommendations for key preanalytics for tissue and blood specimens. If used for biospecimens from patients, these preanalytical recommendations would ensure the fitness of those specimens for molecular analysis and help to assure the quality and reliability of the analysis data.
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE
Perez, Edith A. , Barrios, Carlos H. , Eiermann, W., Im, Young‐Hyuck , Conte, PierFranco , Pieńkowski, Tadeusz , Burris, Howard A. , Petersen, Jennifer, Haas, Sanne de , Hoersch, Silke, Patre, Monika, Ellis, Paul Anthony, Conte, Pierfranco , Toi, Masakazu , Martín, Miguel , Pivot, Xavier B. , Petersen, Jennifer A.

Mayo Clinic

Cancer | July 18, 2019 | Volume: 125 | Issue: 22 | Pages: 3974-3984

10.1002/cncr.32392 | PMID 31318460 Get It

Background In the phase 3 MARIANNE trial, trastuzumab emtansine (T‐DM1) with or without pertuzumab showed noninferior progression‐free survival and better tolerability than trastuzumab plus a taxane (HT) for the first‐line treatment of human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer. This article reports the final descriptive overall survival (OS) analysis, updated safety data, and additional patient‐reported outcomes and biomarker analyses. Methods OS was assessed in 1095 patients with HER2‐positive breast cancer and no prior therapy for advanced disease who had been randomized to HT, T‐DM1 plus a placebo (hereafter T‐DM1), or T‐DM1 plus pertuzumab (T‐DM1+pertuzumab). A post hoc exploratory landmark analysis of OS, baseline patient and disease characteristics, and tumor biomarkers in patients with and without an objective tumor response (OR) according to the Response Evaluation Criteria in Solid Tumors within 6.5 months of randomization was conducted. Results The median OS was similar across groups (50.9, 53.7, and 51.8 months for the HT, T‐DM1, and T‐DM1+pertuzumab groups, respectively). Among patients with an OR, the median OS was longer with T‐DM1 (64.4 months) and T‐DM1+pertuzumab (not reached) versus HT (56.3 months). No baseline characteristics or biomarkers were strongly associated with OR. The incidence of grade 3 or higher adverse events was greater with HT (55.8%) than T‐DM1 (47.1%) or T‐DM1+pertuzumab (48.6%). The median time to clinically meaningful deterioration (a 3‐point or greater change) in neurotoxicity symptoms was shorter with HT (2.1 months) and T‐DM1+pertuzumab (4.2 months) than T‐DM1 (6.2 months). Fewer patients reported alopecia and diarrhea and were bothered by treatment side effects in the T‐DM1 arm. Conclusions These results support T‐DM1 as a first‐line treatment for patients with HER2‐positive metastatic breast cancer who are deemed unsuitable for taxane‐based therapy.
Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial).
Diab, Adi , Marcondes, Mario Q., Kotzin, Brian L. , Tagliaferri, Mary , Hoch, Ute , Cattaruzza, Fiore, Zalevsky, Jonathan , Bilen, Mehmet Asım , Gupta, Shilpa , Domingo‐Musibay, Evidio , Borazanci, Erkut , Curti, Brendan D. , Borazanci, Erkut , Li, Yunfeng , Brohl, Andrew S. , Brugarolas, James , Conley, Anthony P. , D'Angelo, Sandra P

Mayo Clinic

Journal of Clinical Oncology | July 11, 2019 | Volume: 37 | Issue: 8_suppl | Pages: 26-26

10.1200/jco.2019.37.8_suppl.26 Get It

26 Background: NKTR-262 is a novel intratumoral prodrug designed to promote tumor antigen release, an immune stimulatory environment, and antigen presentation. NKTR-214 increases CD8+ T cells and NK cells in the tumor microenvironment. The combination of NKTR-262 with NKTR-214 accesses innate and adaptive immunity to provide an abscopal response and systemic tumor immunity. The Phase 1b/2 REVEAL trial is enrolling. Methods: In a 3+3 Phase 1 design, pts who are relapsed/refractory to ≥1 CPI receive escalating doses of intratumoral (IT) NKTR-262 followed by combined q3w treatment of IT NKTR-262 and fixed-dose intravenous (IV) NKTR-214 (0.006 mg/kg). Phase 1 will evaluate PK, safety, efficacy, and determine recommended Phase 2 dose. Scans are conducted every 9 wks (± 1 wk). Peripheral blood (PB) and tumor tissue are collected to measure biomarkers of immune activation. In Phase 2 expansion, NKTR-262 + NKTR-214 ± IV nivolumab (360 mg) will be assessed in specific tumor cohorts of IO-naïve and experienced pts. Results: As of 06 Nov 2018, 11 pts had received at least one cycle of NKTR-262 + NKTR-214 therapy. 7/11 pts were efficacy evaluable with at least one on-treatment scan (4 MEL, 2 SARC, 1 CRC). 2/4 R/R melanoma pts had uPRs with 100% (scan 2) and 40% (scan 1) reductions in target lesions per RECIST 1.1, respectively. Both patients remain on treatment. Two SARC pts had stable disease at scan 1. No pts experienced G3 or higher TRAEs or immune-related adverse events (AEs). Most common G1-2 AEs were transient flu-like symptoms. Gene expression analysis of tumor and PB show dose-dependent induction (4 to 16-fold) of TLR target genes. Consistent with the mechanism of action for NKTR-214, PB flow cytometry shows an average 13-fold increase from baseline in Ki67+ CD8+T cells in 6 pts. Conclusions: NKTR-262 + NKTR-214 engage the immune activation cascade from local tumor antigen production to anti-tumor T cell response. Initial dose levels of NKTR-262 with fixed-dose NKTR-214 were well-tolerated with early evidence of clinical activity. These data support continued evaluation of the combination +/- nivolumab. Clinical trial information: NCT03435640.
Enablers and Barriers to Implementing ICU Follow-Up Clinics and Peer Support Groups Following Critical Illness: The Thrive Collaboratives*
McPeake, Joanne , Hibbert, Elizabeth , Boehm, Leanne M. , Aparanji, Krishna, Bakhru, Rita N. , Bastin, Anthony J. , Beesley, Sarah J. , Beveridge, Lynne , Butcher, Brad W. , Drumright, Kelly, Eaton, Tammy L. , Firshman, Penelope , Fritschle, Andrew, Hope, Aluko A. , Johnson, Annie, Kenes, Michael T. , Khan, Babar , Kloos, Janet A. , Kross, Erin K. , MacTavish, Pamela , Meyer, Joel , Montgomery-Yates, Ashley , Quasim, Tara , Saft, Howard L., Slack, Andrew, Stollings, Joanna L. , Weinhouse, Gerald L., Whitten, Jessica, Netzer, Giora, Hopkins, Ramona O., Iwashyna, Theodore J. , Sevin, Carla M. , Haines, Kimberley , Farley, Thomas, Holdsworth, Clare, Mikkelsen, Mark E.

Mayo Clinic

Critical Care Medicine | June 28, 2019 | Volume: 47 | Issue: 9 | Pages: 1194-1200

10.1097/ccm.0000000000003818 | PMID 31241499 Get It

Objectives: Data are lacking regarding implementation of novel strategies such as follow-up clinics and peer support groups, to reduce the burden of postintensive care syndrome. We sought to discover enablers that helped hospital-based clinicians establish post-ICU clinics and peer support programs, and identify barriers that challenged them. Design: Qualitative inquiry. The Consolidated Framework for Implementation Research was used to organize and analyze data. Setting: Two learning collaboratives (ICU follow-up clinics and peer support groups), representing 21 sites, across three continents. Subjects: Clinicians from 21 sites. Measurement and Main Results: Ten enablers and nine barriers to implementation of “ICU follow-up clinics” were described. A key enabler to generate support for clinics was providing insight into the human experience of survivorship, to obtain interest from hospital administrators. Significant barriers included patient and family lack of access to clinics and clinic funding. Nine enablers and five barriers to the implementation of “peer support groups” were identified. Key enablers included developing infrastructure to support successful operationalization of this complex intervention, flexibility about when peer support should be offered, belonging to the international learning collaborative. Significant barriers related to limited attendance by patients and families due to challenges in creating awareness, and uncertainty about who might be appropriate to attend and target in advertising. Conclusions: Several enablers and barriers to implementing ICU follow-up clinics and peer support groups should be taken into account and leveraged to improve ICU recovery. Among the most important enablers are motivated clinician leaders who persist to find a path forward despite obstacles.
Heme oxygenase-2 protects against ischemic acute kidney injury: influence of age and sex
Nath, Karl A. , Grande, Joseph P. , Croatt, Anthony J., Ackerman, Allan W., Farrugia, Gianrico , Katušić, Zvonimir S. , Belcher, John D. , Vercellotti, Gregory M. , Grande, Joseph P , Farrugia, Gianrico , Garovic, Vesna D.

Mayo Clinic

American Journal of Physiology-Renal Physiology | June 19, 2019 | Volume: 317 | Issue: 3 | Pages: F695-F704

10.1152/ajprenal.00085.2019 | PMID 31215802 Get It

Heme oxygenase (HO) activity is exhibited by inducible (HO-1) and constitutive (HO-2) proteins. HO-1 protects against ischemic and nephrotoxic acute kidney injury (AKI). We have previously demonstrated that HO-2 protects against heme protein-induced AKI. The present study examined whether HO-2 is protective in ischemic AKI. Renal ischemia was imposed on young and aged HO-2+/+ and HO-2−/− mice. On days 1 and 2 after renal ischemia, there were no significant differences in renal function between young male HO-2+/+ and HO-2−/− mice, between young female HO-2+/+ and HO-2−/− mice, or between aged female HO-2+/+ and HO-2−/− mice. However, in aged male mice, HO-2 deficiency worsened renal function on days 1 and 2 after ischemic AKI, and, on day 2 after ischemia, such deficiency augmented upregulation of injury-related genes and worsened histological injury. Renal HO activity was markedly decreased in unstressed aged male HO-2−/− mice and remained so after ischemia, despite exaggerated HO-1 induction in HO-2−/− mice after ischemia. Such exacerbation of deficiency of HO-2 protein and HO activity may reflect phosphorylated STAT3, as activation of this proinflammatory transcription factor was accentuated early after ischemia in aged male HO-2−/− mice. This exacerbation may not reflect impaired induction of nephroprotectant genes, since the induction of HO-1, sirtuin 1, and β-catenin was accentuated in aged male HO-2−/− mice after ischemia. We conclude that aged male mice are hypersensitive to ischemic AKI and that HO-2 mitigates such sensitivity. We speculate that this protective effect of HO-2 may be mediated, at least in part, by suppression of phosphorylated STAT3-dependent signaling.
Health Misinformation and the Power of Narrative Messaging in the Public Sphere
Murdoch, Blake , Brown, Jasmine M., Perrault, Sarah Tinker, Jarry, Jonathan, Anthony, Samantha J. , Ogbogu, Ubaka , Greenberg, Joshua , Zarzeczny, Amy , Hyde-Lay, Robyn, Caulfield, Timothy , Marcon, Alessandro R , Snyder, Jeremy , Brooks, Stephanie P. , Master, Zubin , Rachul, Christen M.

Mayo Clinic

Canadian Journal of Bioethics | June 18, 2019 | Volume: 2 | Issue: 2 | Pages: 52-60

10.7202/1060911ar Get It

Numerous social, economic and academic pressures can have a negative impact on representations of biomedical research. We review several of the forces playing an increasingly pernicious role in how health and science information is interpreted, shared and used, drawing discussions towards the role of narrative. In turn, we explore how aspects of narrative are used in different social contexts and communication environments, and present creative responses that may help counter the negative trends. As traditional methods of communication have in many ways failed the public, changes in approach are required, including the creative use of narratives.
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Tallman, Martin S. , Wang, Eunice S. , Altman, Jessica K. , Appelbaum, Frederick R. , Bixby, Dale L. , Coutré, Steven , Fathi, Amir T. , Fiorella, Melanie, Foran, James M. , Hall, Aric C. , Jacoby, Meagan A., LeBlanc, Thomas W. , Mannis, Gabriel N. , Marcucci, Guido , Martin, Michael G. , O’Donnell, Margaret, Olin, Rebecca L. , Peker, Deniz , Perl, Alexander E. , Pratz, Keith W. , Shami, Paul J. , Stone, Richard M. , Strickland, Stephen A. , Wieduwilt, Matthew J. , Gregory, Kristina M., OCN, Hammond, Lydia J., Ogba, Ndiya , Wang, Eunice S. , Strickland, Stephen Anthony , Leblanc, Thomas , Bhatt, Vijaya Raj , Lima, Marcos de , Lancet, Jeffrey E. , Mims, Alice S , Pollyea, Daniel Aaron , Prébet, Thomas , Ravandi, Farhad , OCN

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 17, 2019 | Volume: 17 | Issue: 6 | Pages: 721-749

10.6004/jnccn.2019.0028 | PMID 31200351 Get It

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.
SuO007CYCLOPHILINS A AND B OPPOSITELY REGULATE RENAL TUBULAR EPITHELIAL CELL PHENOTYPE
Durán, Mónica , Croatt, Anthony J., Nath, Karl, Salcedo, María Teresa, Bram, Richard J. , Sarró, Eduard , Rico, Ana, Gundelach, Justin H. , Batlle, Daniel , Meseguer, Anna

Mayo Clinic

Nephrology Dialysis Transplantation | June 13, 2019 | Volume: 34 | Issue: Supplement_1 | Pages: No page available

10.1093/ndt/gfz102.suo007 Get It

An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant
Whitwell, Jennifer L. , Stevens, Chase A., Martin, Peter R. , Botha, Hugo , Spychalla, Anthony J., Senjem, Matthew L. , Jack, Clifford R. , Ali, Farwa , Hassan, Anhar , Josephs, Keith A. , Strand, Edythe A. , Jack, Clifford R , Senjem, Matthew L , Botha, Hugo , Duffy, Joseph R. , Clark, Heather M. , Machulda, Mary M. , Utianski, Rene L. , Schwarz, Christopher G.

Mayo Clinic

Movement Disorders Clinical Practice | May 30, 2019 | Volume: 6 | Issue: 6 | Pages: 452-461

10.1002/mdc3.12796 | PMID 31392246 Get It

ABSTRACTBackgroundThe Movement Disorder Society clinical criteria for progressive supranuclear palsy (PSP) provide a framework for assessing the presence/severity of clinical symptoms and define a speech/language variant of PSP.ObjectivesTo evaluate the clinical criteria in a cohort of speech/language patients with longitudinal follow‐up.MethodsA total of 52 patients presenting with progressive apraxia of speech and/or agrammatic aphasia were followed longitudinally for up to 6 visits with clinical assessments and magnetic resonance imaging. We assessed oculomotor, postural instability, and akinesia diagnostic levels and determined whether patients met criteria for possible PSP‐speech/language or probable PSP at each visit. Kaplan‐Meier curves assessed time‐to‐event probabilities according to age. Statistical parametric mapping and midbrain volume were assessed according to disease progression.ResultsFew PSP symptoms were observed early in the disease, with oculomotor abnormalities and falls first observed 2 years after onset. Falls were more common than vertical supranuclear gaze palsy. Bradykinesia and rigidity commonly developed but axial was rarely greater than appendicular rigidity. During follow‐up, 54% met criteria for possible PSP‐speech/language, 38% for probable PSP‐Richardson's syndrome, and 38% for probable PSP‐parkinsonism, most commonly 6 to 6.9 years after onset. The probability of developing PSP was greater when onset was at an age older than 70 years. Patients who progressed to probable PSP had more parkinsonism and oculomotor impairment at baseline and greater midbrain atrophy when compared with those who did not develop probable PSP.ConclusionsSymptoms typical of PSP commonly develop in patients presenting with a progressive speech/language disorder. Older age appears to be an important prognostic factor in these patients.